AIM 26 Summary
Immunodiagnostic System Holdings PLC (IDS) is a global medical diagnostics business dedicated to the development and provision of innovative automated and manual assays. Our development focus is in the clinical areas of bone and calcium metabolism, growth, hypertension and kidney disease. Our IDS-iSYS system provides a compact bench top system that fully automates immunoassay testing.
IDS designs, manufactures and sells immunoassay kits, which are used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies. IDS manufactures manual assays as well as automated assays for use on its reliable and easy to use IDS-iSYS instrument. It has manufacturing sites in the UK, Belgium and France, and direct distribution in the UK, France, Germany, the US and Brazil. Other territories are served through third-party distributors.
- Patricio Lacalle – CEO
- Dr B Wittek – Chairman
- Mr R Sackers – Non-executive Director
- Mr T B Campe – Non-executive Director
- MR P Williamson – Non-executive Director
The Board has overall responsibility for determining and directing the Group’s corporate strategy. It considers and approves the annual business plan and monitors performance of the Group against that plan.
As an AIM listed company, IDS is not obliged to comply with the UK Corporate Governance Code published in September 2012 (“Code”) but instead uses its provisions as a guide, only as considered appropriate to the circumstances of IDS. The Board is committed to achieving and maintaining high standards of Corporate Governance and therefore fully supports the principles of the new UK Corporate Governance Code (September 2012). In adopting the principles of good governance, the Directors have taken into consideration the Quoted Companies Alliance (QCA) Corporate Governance Code for Small and Mid-Size Quoted Companies 2013. The latest full Corporate Governance Report can be found here.
IDS is subject to the UK City Code on Takeovers and Mergers.
England and Wales.
IDS is incorporated in England and Wales. Its main country of operation is England, however it has significant distribution and manufacturing sites in Europe and the USA.
Number of AIM securities in issue as at 1st October 2015:29,415,175
Nil
Percentage of AIM securities not in public hands as at 1st October 2015: 27.06%
| Company Name | Number of ordinary shares of 2p each | Percentage of issued share capital |
| Forum European Smallcaps GmbH | 989,876 | 3.37% |
| Forum Venture Capital GmbH | 6,936,188 | 23.58% |
| BNY Mellon Service Kapitalanlage GmbH | 2,795,252 | 9.50% |
| Axxion S.A. | 2,469,648 | 8.40% |
| Schroders plc | 2,364,000 | 8.04% |
| Polar Capital European Forager Fund Ltd | 1,551,572 | 5.27% |
| Norges Bank | 1,157,219 | 3.93% |
| Shareholder Value Beteiligungen AG | 1,045,000 | 3.55% |
| Quantum Partners LP | 1,031,343 | 3.51% |
The details of major shareholders are based on the notifications received by the Company, under the Disclosure and Transparency Rules, of the percentage of voting rights held. This information may not be up to date as shareholders are only required to provide notification to the Company if their shareholding reaches, exceeds or falls below 3% and each 1% threshold above 3%. Further, in accordance with AIM Rule 26, this information is only updated every six months
Restrictions on the transfer of AIM securities: N/A
Latest Annual Report: Year ended 31 March 2014
Latest Interim Report: 6 months ended 30 September 2014
RNS notifications in the last 12 months can be found here